Stockreport

ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF ADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to Sanofi ADEL's proprietary platform targeting tau modification (acetylation) [Read more]